ELVN Enliven Therapeutics, Inc.
$54.32▼ -3.40%
Healthcare
Other
After hours
$54.32▲ +0.00%
Sep 11, 7:53 PM ET
Volume 995.8K
Avg Volume (10D) 906.6K
Key Metrics & Fundamentals
Market Cap
$3.98B
P/E Ratio
–
Div Yield
–%
52W Range
14.79 - 62.32
% vs 50 MA
-3.35%
% vs 200 MA
41.71%
RSI-14
36.0
MACD Histogram
-0.7700
Beta (1Y vs SPY)
1.04
Free Cash Flow
-$18.63M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$37.20M
COGS
–
Operating Exp
$37.21M
Operating Income
-$37.21M
EBIT
-$37.21M
Pretax Income
-$32.49M
Net Income
-$32.49M
EPS (Diluted)
-0.49
Price & Volume History
Loading chart…
Recent News
Enliven Therapeutics to Present at Upcoming Investor Conferences
PR Newswire · Sep 3, 2026 8:05 PM
Miners And More Lead Slew Of Stocks To Watch — With This Line In Focus
Investor's Business Daily · Sep 2, 2026 8:00 PM
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
PR Newswire · Aug 31, 2026 10:05 PM
William Blair Initiates Enliven Therapeutics at Outperform
MT Newswires · Aug 18, 2026 11:01 AM
Mizuho Raises Price Target on Enliven Therapeutics to $73 From $62, Keeps Outperform Rating
MT Newswires · Aug 18, 2026 10:58 AM
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target
MT Newswires · Aug 18, 2026 10:30 AM
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
PR Newswire · Aug 5, 2026 8:05 PM
Enliven Therapeutics Insider Sold Shares Worth $263,373, According to a Recent SEC Filing
MT Newswires · Jul 21, 2026 9:27 PM
Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing
MT Newswires · Jul 21, 2026 9:27 PM
Profitable Biotechs Strut Their Stuff As Stock Market Stumbles
Investor's Business Daily · Jul 17, 2026 5:38 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ELVN's money flow as a full page
Social Sentiment
No Reddit posts found for ELVN.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.